4basebio plc (4BB) ORD EUR1
- Add to watchlist
- Create an alert
- This stock can be held in a
1,080.00p
1,096.00p
1,120.00p
£138.30 million
1,080.00p
1,061.00p
484.00p
n/a
5.00p (0.47%) Previous:
5.00p
739
n/a
500
Performance
Not available for this stock.
Fundamental data
Year ending: | 31/12/2022 | 31/12/2021 |
---|---|---|
Revenue (£m) | 0.27 | 0.34 |
Profit before tax (£m) | (5.93) | (3.64) |
Adjusted EPS (p): | (42.00) | (26.00) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
4basebio to provide synthetic DNA to tier-one pharma firm
10 April 2024 11:55
-
4basebio client gets approval to start trial in Australia
21 March 2024 16:11
-
4basebio inks significant DNA supply contract
1 March 2024 13:42
-
4basebio announces the supply of its opDNA™ DNA products into Tier 1 Pharma client's vaccine program
10 April 2024 07:00
-
4basebio awarded tender to deliver research and GMP-grade synthetic DNA in CPI's tender process for supplying its RNA Centre of
1 March 2024 07:00
-
Holding(s) in Company
6 February 2024 07:01
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.